Innovative immune therapy with antibiotics to treat deadly inflammation in sepsis and ARDS in older adults
Official title: An Innovative Immune Therapy with Antibiotics to Treat Deadly Excess Inflammation in Sepsis and ARDS Induced from Severe Bacterial Infection in Geriatric Patients
Funded at Bioprovar Corporation · NIH-11417998 · Data updated 2026-11-12
A new approach combines an antibiotic strategy with a special immune-based treatment to help older patients who have sepsis or ARDS from severe bacterial infection.
Quick facts
| Grant type | NIH-funded research |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Bioprovar Corporation NIH-funded |
| Lab location | 1 site (Houston, United States) |
| Project start | September 30, 2021 |
| Project end | May 31, 2027 |
| Funding year | 2026 |
| Award (this year) | $349,073 |
| NIH project number | 5U44AG074105-03 |
| Project ID | NIH-11417998 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates are geriatric patients with severe bacterial infections leading to sepsis or ARDS who might benefit from immune-modulating therapy alongside antibiotics.
✕Less likely to help
Patients whose sepsis/ARDS is not driven by the studied TREM1 pathway or who cannot receive antibiotics may see limited or no benefit.
What this research studies
This project focuses on a targeted immune therapy that works alongside antibiotics to calm an overactive inflammatory response in older patients with sepsis- or ARDS-related illness. It builds on evidence that a TREM1 pathway can drive dangerous inflammation and tests a natural receptor variant to modulate that response. The work is described in animal models and aims to translate the approach toward human application, with emphasis on safety and potential survival benefits. If successful, it could lead to a new treatment option for a high-risk patient group facing life-threatening infections.
Why it matters
Potential benefit: If successful, the therapy could reduce inflammation and improve survival in seniors with sepsis and ARDS.
How similar studies have gone: Previous animal studies showed improved survival with the TREM1-sv approach, but human results are not yet established.
Where this research is happening
-
Bioprovar Corporation
Houston, United States Active
Researchers
- Principal investigator: Roussel, Eugene — Bioprovar Corporation
- Study coordinator: Roussel, Eugene
Related research
Other NIH-funded projects on the same topics.
-
A new immune-blocking therapy plus antibiotics for severe sepsis and ARDS in older adults
This project is trying a treatment that restores a natural TREM1 blocker together with antibiotics to help older adults with life-threatening bacterial sepsis or ARDS.
-
Using immune therapy and antibiotics to treat severe inflammation in older patients with sepsis and ARDS.
This study is looking at a new way to help older adults with sepsis and severe breathing problems by using a mix of immune therapy and antibiotics, focusing on a special immune receptor that might help reduce harmful inflammation and improve their chances of recovery.
-
Coordinating ARDS, Pneumonia, and Sepsis research to improve care
A national coordinating center helps researchers studying ARDS and related infections work together more efficiently to learn what helps patients recover.
-
Understanding ARDS, pneumonia, and sepsis: a big study to map how illness and recovery unfold
A large patient study at the University of Pennsylvania will follow adults with ARDS, pneumonia, or sepsis to learn how these conditions progress and recover over time.
-
Coordination and data sharing for ARDS, pneumonia, and sepsis research
A national collaborative effort to improve how researchers study ARDS, pneumonia, and sepsis by coordinating centers, data collection, and analyses.
-
Molecular profiling of ARDS, pneumonia, and sepsis in adults using advanced sequencing
A research team at four California hospitals will study adults with ARDS, pneumonia, or sepsis to identify molecular patterns in their illness using genetic sequencing.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.